Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies

(2018) Gang Xiao et al.   CELL

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia

(2018) Damian Lai et al.   Science Translational Medicine

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

(2016) Vincent Chung et al.   CLINICAL CANCER RESEARCH

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies

(2015) Maria Ciccone et al.   Frontiers in Oncology

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

(2008) Liang L. Zhou et al.   JOURNAL OF EXPERIMENTAL MEDICINE